Literature DB >> 10463718

Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease.

B M Psaty1, N S Weiss, C D Furberg, T D Koepsell, D S Siscovick, F R Rosendaal, N L Smith, S R Heckbert, R C Kaplan, D Lin, T R Fleming, E H Wagner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10463718     DOI： 10.1001/jama.282.8.786

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  44 in total

Review 1.  Biomarkers as surrogates for cancer development.

Authors:  E Hawk; J L Viner; J A Lawrence
Journal:  Curr Oncol Rep       Date:  2000-05       Impact factor: 5.075

2.  British guidelines on managing hypertension. Provide evidence, progress, and an occasional missed opportunity.

Authors:  B M Psaty; C D Furberg
Journal:  BMJ       Date:  1999-09-04

3.  Evidence-based medicine: worship of form and treatment of high blood pressure.

Authors:  B M Psaty; C Rhoads; C D Furberg
Journal:  J Gen Intern Med       Date:  2000-10       Impact factor: 5.128

Review 4.  Cost per millimeter of mercury lowering is a measure of economic value for antihypertensive agents.

Authors:  R S Chen; P Lapuerta
Journal:  Curr Hypertens Rep       Date:  2000-12       Impact factor: 5.369

Review 5.  The challenges of conducting clinical endpoint studies.

Authors:  Jonathan L Isaacsohn; Tiffany A Khodadad; Catherine Soldano-Noble; Jeffrey D Vest
Journal:  Curr Atheroscler Rep       Date:  2003-01       Impact factor: 5.113

Review 6.  Interpretation of observational studies.

Authors:  P Jepsen; S P Johnsen; M W Gillman; H T Sørensen
Journal:  Heart       Date:  2004-08       Impact factor: 5.994

7.  Clinical trials and tribulations--lessons from pulmonary fibrosis.

Authors:  A L Olson; J J Swigris; K K Brown
Journal:  QJM       Date:  2012-05-29

8.  Drug therapies for the primary prevention of cardiovascular events: trials and errors: 2009 Ancel Keys Memorial Lecture.

Authors:  Bruce M Psaty
Journal:  Circulation       Date:  2010-02-23       Impact factor: 29.690

Review 9.  Pharmacogenetics of response to statins: where do we stand?

Authors:  Anke-Hilse Maitland-van der Zee; Eric Boerwinkle
Journal:  Curr Atheroscler Rep       Date:  2005-05       Impact factor: 5.113

Review 10.  Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices?

Authors:  Robert E Becker; Nigel H Greig; Ezio Giacobini
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.